Structural and Functional Studies of a Bothropic Myotoxin Complexed to Rosmarinic Acid: New Insights into Lys49-PLA2 Inhibition by dos Santos, Juliana I. et al.
Structural and Functional Studies of a Bothropic
Myotoxin Complexed to Rosmarinic Acid: New Insights
into Lys49-PLA2 Inhibition
Juliana I. dos Santos
1,2,F a ´bio F. Cardoso
3, Andreimar M. Soares
4, Maeli dal Pai Silva
5,M a ´rcia Gallacci
3*,
Marcos R. M. Fontes
1,2*
1Departamento de Fı ´sica e Biofı ´sica, Instituto de Biocie ˆncias, University Estadual Paulista, Botucatu/Sao Paulo, Brazil, 2Instituto Nacional de Cie ˆncia e Tecnologia em
Toxinas, Conselho Nacional de Desenvolvimento Cientı ´fico e Tecnolo ´gico, Botucatu/Sao Paulo, Brazil, 3Departamento de Farmacologia, Instituto de Biocie ˆncias,
University Estadual Paulista, Botucatu/Sao Paulo, Brazil, 4Fundac ¸a ˜o Oswaldo Cruz - Rondo ˆnia and Centro de Estudos de Biomole ´culas Aplicadas, Universidade Federal de
Rondo ˆnia, Porto Velho/Rondonia, Brazil, 5Departamento de Morfologia, Instituto de Biocie ˆncias, University Estadual Paulista, Botucatu/Sao Paulo, Brazil
Abstract
Snakebite envenoming is an important public health problem in many tropical and subtropical countries, and is considered
a neglected tropical disease by the World Health Organization. Most severe cases are inflicted by species of the families
Elapidae and Viperidae, and lead to a number of systemic and local effects in the victim. One of the main problems
regarding viperidic accidents is prominent local tissue damage whose pathogenesis is complex and involves the combined
actions of a variety of venom components. Phospholipases A2 (PLA2s) are the most abundant muscle-damaging
components of these venoms. Herein, we report functional and structural studies of PrTX-I, a Lys49-PLA2 from Bothops
pirajai snake venom, and the influence of rosmarinic acid (RA) upon this toxin’s activities. RA is a known active component
of some plant extracts and has been reported as presenting anti-myotoxic properties related to bothopic envenomation.
The myotoxic activity of Lys49-PLA2s is well established in the literature and although no in vivo neurotoxicity has been
observed among these toxins, in vitro neuromuscular blockade has been reported for some of these proteins. Our in vitro
studies show that RA drastically reduces both the muscle damage and the neuromuscular blockade exerted by PrTX-I on
mice neuromuscular preparations (by ,80% and ,90%, respectively). These results support the hypothesis that the two
effects are closely related and lead us to suggest that they are consequences of the muscle membrane-destabilizing activity
of the Lys49-PLA2. Although the C-terminal region of these proteins has been reported to comprise the myotoxic site, we
demonstrate by X-ray crystallographic studies that RA interacts with PrTX-I in a different region. Consequently, a new mode
of Lys49-PLA2 inhibition is proposed. Comparison of our results with others in the literature suggests possible new ways to
inhibit bothropic snake venom myotoxins and improve serum therapy.
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Introduction
Envenoming resulting from snakebites is an important public
health problem in many tropical and subtropical countries [1,2].
Although data on this topic are scarce, a recent study estimates
that at least 421,000 envenomations and 20,000 deaths due to
snakebites occur each year [2]. This problem is particularly
important in the rural tropics because the populations of these
areas usually have poor access to health systems and, in some
cases, antivenom is scarce [1,3]. A large number of victims survive
with permanent physical and also psychological sequelae. Young
agricultural workers, especially males, are the most affected group,
making snakebite envenoming a truly occupational disease [1]
now considered a neglected tropical disease by the World Health
Organization (WHO; http://www.who.int/neglected_diseases/
diseases/snakebites/en/index.html). Even though the majority of
deaths due to snakebite envenoming occur in south and south-east
Asia and sub-Saharan Africa [2], these accidents are also an
important health problem in Latin America [4] where snakebites
from the Bothrops genus (Viperidae family) are responsible for more
than 85% of all reported ophidian accidents [5,6]. One of the
main problems associated with these events is prominent local
tissue damage characterized by swelling, blistering, hemorrhaging
and necrosis of the skeletal muscle which develops rapidly after the
snakebite [1]. Consequently, a delay in access to health facilities
frequently results in drastic tissue damage and permanent
disability [1,7–11].
The pathogenesis of myonecrosis is complex and involves the
combined actions of a variety of venom components, such as
myotoxins and metalloproteinases [12–18]. Nowadays, parenteral
administration of animal-derived antivenoms that consist of whole
IgG molecules (,150 kDa), F(ab9)2 or Fab fragments [19–22]
constitutes the only specific treatment for snakebite envenoming.
But despite the success of this therapy in neutralizing toxins
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antivenom presents a limited effectiveness in protecting against
establishment of myonecrosis [23]. Therefore, advances in the
treatment of this local pathology may be achieved by elucidating
the snake venom components involved in its genesis and the
molecular basis of their mechanism of action.
Phospholipases A2 (PLA2s) are the most abundant proteins
found in Viperidae snake venoms [24] and, in addition to their
well-established ability to hydrolyze lysophospholipids in a
calcium-dependent mechanism [25], these proteins can display
toxic effects by different mechanisms [26]. A recent phylogenetic
study shows that snake venom PLA2s can be classified into two
groups according to their evolutionary derivation: i) the calcium-
dependent catalytically active enzymes, such as Asp49-, Asn49-
and Gln49-PLA2s; and ii) the catalytically inactive PLA2s that
exert their effects through a still unresolved calcium-independent
mechanism (Lys49-, Arg49- and some Asp49-PLA2s) [27]. The
former group usually includes acidic PLA2s that act as monomeric
toxins whereas the latter includes basic PLA2s that adopt a
homodimeric configuration [27].
Despite their lack of enzymatic activity, Lys49-PLA2 myotoxins
play a key role in myonecrosis, given that when they are selectively
neutralized, most of the muscle-damaging effect of whole venoms
is prevented [28–32]. In addition, several other biological activities
have been described for these toxins both in vivo and in vitro [15].
Although myotoxic Lys49-PLA2s are devoid of significant
neurotoxicity in vivo [15], some of them are able to induce an
inhibitory neuromuscular activity in vitro [33–38]. Recently, a
review of experimental evidence on this topic has suggested that
both the in vitro neuromuscular blockade and the muscle damage
induced by Lys49-PLA2s are consequences of their general muscle
membrane-destabilizing activity [38].
Studies involving the interaction of myotoxic Lys49-PLA2s with
potential neutralizing molecules have been one of the main
methodologies employed to elucidate the action mechanism and
structural determinants of the biological activities of these toxins
[35,39–42]. Furthermore, PLA2 inhibitors may provide therapeu-
tic molecular models with antiophidian properties and may be
applicable as a supplement to the conventional serum therapy
[42]. Medicinal plants constitute an important source of bioactive
compounds able to antagonize the activity of various crude
venoms and purified toxins [40,42–53]. In 2005, Ticli and
colleagues showed that rosmarinic acid (RA) isolated from Cordia
verbenacea significantly inhibits the myotoxic effect induced by the
two main basic PLA2s homologues (BthTX-I and BthTX-II) from
Bothrops jararacussu snake venom [40]. The authors also demon-
strated that RA enhances the effect of commercial equine
polyvalent antivenom against isolated myotoxins or the crude
venom [40].
In this work we report structural and functional studies
concerning the mechanism through which RA neutralizes the in
vitro inhibitory neuromuscular effect and muscle damage caused by
PrTX-I, a Lys49-PLA2 from Bothops pirajai snake venom [54]. The
data obtained show that RA is able to drastically reduce both the
muscle damage and the neuromuscular blockade caused by the
toxin, supporting the hypothesis that these two effects are mainly
consequences of the muscle membrane-destabilizing activity of
Lys49-PLA2s. X-ray crystallographic studies demonstrate that RA
interacts with PrTX-I at the entrance of its hydrophobic channel
and not at its C-terminus, a region indicated as responsible for the
myotoxic effects of Lys49-PLA2s [15,55–59]. Comparison of our
results with others available in the literature lead us to suggest
possible new approaches to inhibit bothropic snake venom
myotoxins so as to achieve improvement in serum therapy.
Methods
Protein purification and Inhibitor Source
PrTX-I was isolated from Bothrops pirajai snake venom as
previously described [54] and rosmarinic acid (RA) was purchased
from Sigma-Aldrich.
Functional Studies
Animals. Adult male mice weighing 25–30g were maintained
under a 12 h light-dark cycle (lights on at 07:00 AM) in a
temperature-controlled environment (2262uC) for at least 10 days
prior to the experiments. Food and water were freely available.
Animal procedures were in accordance with the guidelines
prepared by the Committee on Care and Use of Laboratory
Animal Resources, National Research Council, USA.
Neuromuscular-blocking activity. Mice were killed by
exsanguination after ether anesthesia. Phrenic-diaphragm
preparation was removed and mounted vertically in a
conventional isolated organ-bath chamber containing 15 mL of
physiological solution of the following composition (mmol/L):
NaCl, 135; KCl, 5; MgCl2, 1; CaCl2, 2; NaHCO3, 15; Na2HPO4,
1; glucose, 11. This solution was bubbled with carbogen (95% O2
and 5% CO2). The preparation was attached to an isometric force
transducer (Grass, FT03) to record the twitch tension. The
transducer signal output was amplified and recorded on a
computer via a transducer signal conditioner (Gould, 13-6615-
50) with an AcquireLab Data Acquisition System (Gould). The
resting tension was 5 g. Indirect contractions were evoked by
supramaximal pulses (0.2 Hz, 0.5 ms) delivered from an electronic
stimulator (Grass-S88K) and applied to the phrenic nerve by
means of a suction electrode.
The preparation was stabilized for 45 minutes before the
addition of a single concentration of toxin. For inhibition
experiments, a fixed amount of PrTX-I dissolved in physiological
saline solution (PSS; 0.9% NaCl) was mixed with the same
quantity of RA, in order to obtain a 1:1 (w/w) toxin/RA ratio.
Mixtures were incubated for 30 minutes at 3562uC. Control
experiments were performed in the absence of toxin or in the
presence of RA alone. The degree of protection offered by RA
after 90 minutes of contact with the preparation was expressed as
a percentage of neuromuscular blockade observed in the presence
of the mixture of toxin plus RA relative to the blockade seen in the
presence of toxin alone.
Muscle-damaging activity. At the end of the functional
study, phrenic-diaphragm muscle was removed from the bath and
immersed in Bouin’s fixative, processed, and embedded in
Historesin (Kit Historesin Leica). Histological transverse sections
(5 mm thick) were cut out in a microtome and stained with
hematoxylin and eosin (HE) prior to examination by light
microscopy [60]. Muscle samples were also fixed in Karnovsky’s
fixative for 4 h and washed in 1% osmium tetroxide. The tissue
was dehydrated in ascending concentrations of acetone and
embedded in Epon resin. Sections (1.5 mm) were stained with
uranyl acetate and lead citrate, and examined by electron
microscopy.
Morphological damage was quantified in HE-stained prepara-
tions, using an Imaging Analysis System (Leica, Qwin). The
number of fibers with lesions was expressed as a percentage of the
total number of cells (muscle damage index), in three non-
overlapping non-adjacent areas of each muscle, observed at the
same magnification. The degree of neutralization offered by RA
was expressed as a percentage of the myonecrosis index in the
presence of toxin plus RA relative to that index in the presence of
the toxin alone.
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Data were analyzed by ANOVA complemented by the Tukey-
Kramer test. Values of P,0.05 were considered significant.
Structural Studies
Crystallographic studies. Co-crystallization experiments
were performed with PrTX-I at a concentration of 12 mg/mL
[61]. Crystals of the complex were obtained by the sitting drop
method [62] after thirty minutes of protein/ligand pre-incubation.
The best crystals were produced by combining 1 mlo fp r o t e i n
solution, 0.5 ml of RA solution (35 mM) and 1 ml of reservoir solution
and equilibrated against 0.5 ml of the same precipitant solution -
20% PEG4000, sodium citrate pH 5.6 and 20% 2-propanol [61].
X-ray data collection and processing. X-ray diffraction
data were collected at a wavelength of 1.427 A ˚ (at 100 K) using a
synchrotron radiation source (MX2 station - Laborato ´rio Nacional
de Luz Sı ´ncrotron, LNLS, Campinas, Brazil) and a MAR CCD
imaging-plate detector (MAR Research). A crystal was mounted in
a nylon loop and flash-cooled in a stream of nitrogen at 100 K
using no cryoprotectant [61]. Data were processed using the HKL
program package [63].
Structure determination and refinement. The crystal
structures were solved by molecular replacement using the
program Phaser [64] and the coordinates of PrTX-I complexed
with a ´-tocopherol [65] as a model. The model was improved, as
judged by the free R-factor [66], through rounds of crystallographic
refinement using the REFMAC program [67]. Manual rebuilding
was performed with the COOT program [68]. The quality of the
model was checked by the program Procheck [69].
Ligand design. The program Avogadro v.1.0.0 [70] (http://
avogadro.openmolecules.net/) was used to design the RA molecule (3-
(3,4-dihydroxyphenyl)-2-[(E)-3-(3, 4-dihydroxyphenyl)prop-2-enoyl]-
oxypropanoic acid) and improve its overall structure by an energy
minimization process based on the MMFF94 force field [71].
Geometric optimization was performed with a steepest-descent
algorithm (500 steps with a 10
27 convergence criterion).
Results
Neuromuscular blocking activity
PrTX-I (1 mM) induced a time-dependent blockade of indirectly
evoked twitches in phrenic-diaphragm preparations. After 90 min-
utes, thetwitchamplitudes werereduced from100% to 4.5%62.9%
(Figure 1). The mean time required to reduce the twitch amplitudes
by 50% (t1/2)w a s3 1 . 9 63.2 minutes. The neuromuscular blockade
induced by PrTX-I was not reversed when preparations were
washed for 30 minutes with toxin-free physiological solution (data
not shown). RA significantly prevented the neuromuscular blockade
induced by PrTX-I when both were pre-incubated, but alone the
RA did not affect the twitches (Figure 1).
Muscle-damaging activity
Light microscopy showed that a majority of both control
(Figure 2a) and RA-exposed (Figure 2b) diaphragm muscle fibers
presented normal appearance. Fibers were clearly delimited by a
thin layer of connective tissue (the endomysium) and presented a
polygonal shape, acidophilic sarcoplasm and peripheral nuclei
(Figure 2a, b). Few fibers from the control (0.660.1%) and RA-
treated muscles (0.960.1%) were injured (Figure 3). After
90 minutes of contact with PrTX-I, diaphragm muscle presented
fibers with different degrees of damage. The most common
features were round fibers and edema in endomysium connective
tissue that was characterized by larger spaces between fibers.
Many fibers presented cytoplasm areas devoid of myofibrils, some
with a central nucleus (Figure 2c). The muscle damage index was
35.160.7% (Figure 3). Ultra-structural analysis revealed muscle
fibers with loss of myofilaments, leaving sarcoplasmic spaces
apparently devoid of myofibrils. Mitochondria showed swelling
Figure 1. Effects of PrTX-I alone and PrTX-I pre-incubated with RA on indirectly evoked twitches in mouse phrenic-diaphragm
preparations. The ordinate represents the percentage amplitude of twitches relative to the initial amplitude. The abscissa indicates the time after
the addition of toxin to the organ bath. The points are the mean 6 S.E. * indicates the point at which differences between PrTX-I and the control
become significant.
doi:10.1371/journal.pone.0028521.g001
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preparations exposed to PrTX-I that had been pre-incubated with
RA showed most fibers with normal aspects (Figures 2d, 4e and
4f); the muscle damage index was 7.960.9% (Figure 3).
Crystallographic studies
Crystals of the PrTX-I/RA complex diffracted X-rays to 1.77 A ˚
resolution [61]. Data collection statistics are shown in Table 1.
The crystals belong to orthorhombic space group P212121, with
unit-cell parameters a=49.4 A ˚, b=67.0 A ˚ and c=85.5 A ˚. The
data set is 95.1% complete with an Rmerge=6.8%. Calculations
based on the protein molecular weight [72] indicate the presence
of two molecules in the asymmetric unit [61]. The homodimeric
configuration adopted by Lys49-PLA2s has already been demon-
strated by different techniques [39,73–77] and is assumed to be the
biological assembly in this study.
After molecular replacement and cycles of manual and
automated refinement, an electron density that corresponds to
Figure 2. Light micrographs of mouse diaphragm muscles submitted to hematoxilin and eosin staining. Control muscle (a) and muscle
exposed to RA (b) show fibers with normal appearance as evidenced by the polygonal aspect of fibers (F) and endomysium (EN). (c) Muscle exposed
to PrTX-I: edema (ED), round fibers (RF) some of which present loss of myofibrils (LM). (d) Muscle exposed to PrTX-I pre-incubated with RA: most fibers
present a normal appearance.
doi:10.1371/journal.pone.0028521.g002
Figure 3. Effect of RA upon the muscle damage index induced by PrTX-I in mouse diaphragm preparations. The ordinate represents
the % of damaged fibers relative to normal fibers and the abscissa indicates the experimental groups. The bars are expressed as mean 6 S.E.
doi:10.1371/journal.pone.0028521.g003
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channel monomer A (Figure 5; Figure 6) [61]. Inspection of the
|Fobs|-|Fcalc| electronic density map also showed that one
PEG4000 and eight molecules of isopropanol (IOH) also interact
with the toxin. RA establishes hydrogen bonds with residues Phe3,
Lys7, Leu10, Gln11 and Gly15 of monomer A (Figure 5) and
interacts through water molecules with residues Leu2, Arg72 and
Trp77 of the same chain. Additionally, interactions between the
RA molecule and the residue Pro123 of monomer B are observed
(Figure 5). On the other hand, the hydrophobic channel of
monomer B is occupied by a PEG4000 molecule. This PEG
molecule establishes contacts with Phe3 and Lys7 of monomer B,
with the latter being established via a water molecule. Two of the
eight isopropanol (IOH) molecules interact with both His48
residues (Nd1 atoms) of the dimeric structure through the well-
known ‘‘active-site’’ water molecule [78]. Asn17:Tyr119 and
Tyr119:Tyr119 hydrogen bonds are observed between the protein
monomers.
Due to a lack of defined electron density, the side chains of the
following residues were modeled as alanine: Lys36, Lys78, Leu116
and Lys129 of chain A, and Lys70, Leu116 and Lys127 of chain B.
The side chains of some other residues were modeled as presenting
multiple configurations.
Comparison of the PrTX-I/RA complex with the apo PrTX-I
structure [65] (PDB ID 2Q2J) shows that a rearrangement
between the monomers is induced by the presence of RA and
affects mainly one of the C-termini (overall r.m.s.d. of 1.04 A ˚ and
0.59 A ˚ for protomers A and B, respectively, and 2.65 A ˚ and
0.58 A ˚ for their C-termini, respectively) (Figure 7). This
rearrangement can be characterized by the establishment of the
Tyr119-Tyr119 interchain hydrogen bond that is a feature
common to all structures of Lys49-PLA2 complexes solved to
date [65,74,75,79].
Discussion
Myonecrosis is an important consequence of envenomation
following Bothrops snakebites because it is poorly neutralized by
conventional serum therapy and, in severe cases, may lead to
amputation and permanent disability [1,2,4,7,9,80]. Therefore,
there has been a growing interest in the study of venom
components involved in the genesis of myonecrosis, their mode
of action and the structural basis underlying this biological activity.
Several of these investigations have focused on the myotoxic
Lys49-PLA2 homologues that are widely found in Viperidae snake
venoms [15,81,82]. One of the experimental strategies used for the
study of these myotoxins is based on the evaluation of the
functional and structural consequences of their interaction with
potential neutralizing agents. Therefore, in this work we
investigated the ability of RA to neutralize the muscle-damaging
and the neuromuscular-blocking activities of PrTX-I, a Lys49-
PLA2 from Bothrops pirajai snake venom. Additionally, the complex
Figure 4. Electron micrographs of mouse diaphragm muscle. Control muscle (a, b) shows normal morphology with plasma membrane (PM),
myofibrils (M) and mitochondria (MI). Muscle exposed to PrTX-I (c, d) presents fibers with myofibril disorganization (MD), cytoplasmic areas devoido f
myofibrils (DM) and mitochondrial swelling with reduced or ruptured cristae (MS). Muscle exposed to PrTX-I pre-incubated with RA (e, f) shows
normal fiber aspect. Note myofibrils (M) and mitochondria (MI) aspects.
doi:10.1371/journal.pone.0028521.g004
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structural site(s) involved in the toxic effects presented by this
Lys49-PLA2.
The present data show that RA significantly reduces the
blockade of indirectly evoked muscle contractions induced by
PrTX-I by up to 90% and inhibits the muscle damage caused by
this toxin in isolated phrenic-diaphragm preparations by about
80%. The ability of PrTX-I and several other Lys49-PLA2st o
block neuromuscular transmission in isolated preparations has
been previously described [33–38]. However, interpreting this
finding has been a challenging task since these myotoxins are
devoid of significant neurotoxicity in vivo [15]. Nevertheless, a
recent review of all the available experimental evidence led to the
hypothesis that both the in vitro inhibitory neuromuscular effect
and the muscle damage promoted by Lys49-PLA2s result from
their ability to destabilize muscle cell membranes [38]. The first
consequence of the muscle membrane destabilization is the
collapse of the ionic gradient leading to cell depolarization,
probably due to the re-equilibration of Na
+ and K
+ ions [83]. In
fact, initial contractures and reduction of the resting membrane
potential, which indicate membrane cell depolarization, are
characteristics of the in vitro neuromuscular blockade induced by
Lys49-PLA2s in frog, chick and mouse preparations [33,83,84].
Thus, it has been suggested that the persistent cell depolarization
induced by Lys49-PLA2s creates areas of membrane inexcitability
due to inactivation of voltage-dependent Na
+-channels, thus
impairing the generation of the action potential along muscle
fibers [83]. Neuromuscular transmission is highly susceptible to
this depolarizing blockade because it depends on the electrical
excitability of a restricted membrane area surrounding the
endplate region, known as the perijunctional zone [38]. Moreover,
the disruption of the muscle fiber membranes induced by Lys49-
PLA2 homologues also promotes an increase in the concentration
of the cytosolic calcium that initiates a complex series of
degenerative effects on muscle fibers [38,85]. The fact that RA
considerably reduces both the paralysis and the muscle damage
caused by PrTX-I confirms the hypothesis that these effects are
closely related.
Rosmarinic acid is a polyphenolic compound found in various
plants of the Boraginaceae and Laminaceae families [86]. Several
biological properties have been described for this compound
including its ability to neutralize inflammatory, myotoxic and
hemorrhagic activities of both crude snake venoms and their
isolated toxins [40,87]. In addition, it has been shown that RA
inhibits some enzymes including acetylcholinesterase [88,89].
However, this anticholinesterase activity occurs within a concen-
tration range that is one to two orders of magnitude higher than
that used in our experiments [88,89] and probably does not
explain the ability of RA to neutralize PrTX-I-induced neuro-
muscular blockade. Additionally, the observation that RA alone
does not significantly affect the indirectly evoked contractions
supports this idea. Electrophoresis and circular dichroism studies
exclude the proteolytic degradation of the toxin as a potential
mechanism involved in the inhibition of myotoxic and inflamma-
tory activities of Lys49-PLA2s from Bothrops jararacussu venom by
RA [40]. In view of the abovementioned characteristics, RA is an
apt tool for investigating the structural basis underlying the toxic
activities of Lys49-PLA2s and may even become a potential
effective molecule to supplement serum therapy.
The muscle membrane-destabilizing activity exerted by Lys49-
PLA2s has long been attributed to the presence of basic and
aromatic residues situated at specific positions in the C-terminal
region of these toxins [15,55–57,59,90–92] (residues 115–129
according to the numbering system adopted by Renetseder and
colleagues [93]). On the other hand, ligands that bind to other sites
have also been described in the literature and their ability to
diminish the myotoxic effects induced by Lys49-PLA2s have been
demonstrated [39,94–96].
A recent review of all apo and complexed structures of Lys49-
PLA2s available in the Protein Data Bank (http://www.pdb.org)
served as the basis for a prediction of the residues involved in the
muscle membrane-destabilizing activity of these proteins (denom-
inated a ‘‘myotoxic site’’) and a two-step mechanism of action [65]
(Figure 8). According to the proposal, the first step of the
mechanism is the interaction of Lys20, Lys115 and Arg118 of
these proteins with the phospholipid headgroups at the surface of
the plasma membrane. Subsequently, a quaternary rearrangement
takes place that allows long-chain hydrophobic portions of
membrane phospholipids to be inserted into the hydrophobic
channel of the toxin [65]. Therefore, the hydrophobic channel was
suggested to be involved in one of the steps required for the
mechanism of Lys49-PLA2s, thereby justifying its conservation
Table 1. X-ray data collection and refinement statistics for
PrTX-I/RA.
Unit cell (A ˚) a=49.4, b=67.0, c=85.5
Space group P212121
Resolution (A ˚) 40-1.77 (1.86-1.77)
a
Unique reflections 26992 (3895)
a
Completeness (%) 95.1 (97.5)
a
Rmerge
b (%) 6.8 (41.2)
a
Radiation source Synchrotron (MX2 station,
LNLS)
I/s(I) 16.5 (2.0)
a
Matthews coefficient VM (A ˚3/Dalton) 2.62
Molecules in asymmetric unit 2
Solvent content (%) 53.12
Rcryst
c (%) 16.0
Rfree
d (%) 21.7
Mean B-factor (A ˚2)
e
Overall 37.2
Protein 22.7
RA molecule 44.2
R.m.s. deviations from ideal values
e
bond lengths (A ˚) 0.022
bond angles (
o) 2.0
Ramachandran plot
f
residues in most favorable/additionally allowed
region (%)
89.9/9.1
residues in generously/not allowed regions (%) 1.0/0
Coordinate error (A ˚)
SIGMAA (cross-validated SIGMAA)
e 0.07 (0.08)
aNumbers in parenthesis are for the highest resolution shell.
bRmerge=Shkl(Si(|Ihkl,i2,Ihkl .|))/Shkl,i ,Ihkl., where Ihkl,i is the intensity of an
individual measurement of the reflection with Miller indices h, k and l, and
,Ihkl. is the mean intensity of that reflection. Calculated for I.23s (I).
cRcryst=ghkl(IFobshkl|-|FcalchklI)/|Fobshkl|, where |Fobshkl| and |Fcalchkl| are the
observed and calculated structure factor amplitudes.
dRfree is equivalent to Rcryst but calculated with reflections (5%) omitted from
the refinement process.
eCalculated with the program REFMAC [67].
fCalculated with the program PROCHECK [69].
doi:10.1371/journal.pone.0028521.t001
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PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e28521Figure 5. Interactions between RA and PrTX-I atoms in the PrTX-I/RA complex. The surface charge distribution for the PrTX-I/RA
crystallographic model and specific interactions between RA with some PrTX-I atoms are shown. Only the interactions with interatomic distances
shorten than 3.7 A ˚ are represented between chain A and the RA molecule (black dashes). To represent the interactions between RA and the residue
Pro123 of chain B a larger distance cut-off was considered (blue dashes). Residues whose contacts with RA are established through water molecules
are not shown. The electron density map for RA molecule was calculated with coefficients 2|Fobs|-|Fcalc| contoured at 1.0 standard deviation.
doi:10.1371/journal.pone.0028521.g005
Figure 6. Comparison of the PrtX-I/RA complex with two other Lys49-PLA2s complexed to fatty acids. (a) Cartoon representation for the
PrTX-I/RA complex. (b) PrTX-I/RA complex displayed in the same orientation shown in (a) shows RA occluding the entrance of the chain A
hydrophobic channel. A surface representation is used for protomer A and cartoon representation with a semi-tranparent surface is employed for
protomer B. The hydrophobic channel of protomer A is shown in yellow and the C-terminus of protomer B (residues 119–125) is represented in blue.
(c) Superposition of PrTX-I/RA complex with PrTX-II/fatty acid (pink) and MjTX-II/stearic acid (light green) complexes (only one protomer of the
homodimeric toxins is represented). (d) Surface view of the PrTX-I/RA complex shows that the hydrophobic channel of monomer A is in close contact
with the C-terminal region of monomer B. The RA molecule is shown in sticks in all panels.
doi:10.1371/journal.pone.0028521.g006
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activity [65,75].
The crystal structure of PrTX-I complexed to RA shows that
the inhibitor interacts with the toxin at the entrance of its
hydropohobic channel (Figure 5; Figure 6), demonstrating for the
first time a ligand that interacts with this region of a Lys49-PLA2.
Considering the mechanism proposed by dos Santos and
colleagues [65], this finding suggests that the inhibitory effect of
RA is the result of a steric hindrance that blocks the access of
substrates to the hydrophobic channel (Figure 6; Figure 8).
Supporting this hypothesis, comparison of the PrTX-I/RA
complex with structures of two Lys49-PLA2s bound to fatty acids
(PDB ID 1QLL and 1XXS) [97,98] suggests that RA impairs the
binding of lipid tails to the hydrophobic channel by physically
blocking its entrance (Figure 6c). The fact that only one RA
molecule was found to interact with the dimeric structure of
PrTX-I can be rationalized by the presence of a PEG4000
molecule in the second hydrophobic channel, presumably arising
from the high concentration of PEG4000 in the crystallization
buffer combined with the high affinity of the channel for
hydrophobic molecules.
The way RA interacts with PrTX-I lead us to suggest how the
quaternary assembly of the protomers contributes to Lys49-PLA2s
function. The blockade of one hydrophobic channel of the toxin
Figure 7. Superposition of the apo and RA-bound forms of PrTX-I. (a) Ribbon representation of both homodimer structures. (b)
superposition between corresponding protomers of the structure. The r.m.s.d. values for the whole protomer chain superposition and for the C-
terminal region (residues 115–129) are shown. The higher r.m.s.d. for protomer B is due to allosteric changes induced by the ligand in the C-terminal
region.
doi:10.1371/journal.pone.0028521.g007
Figure 8. Model for Lys49-PLA2 interaction with muscle membrane and the influence of RA. Step 1 represents the initial protein-
membrane interactions and step 2 represents the protein after C-termini interactions and insertion of lipid tails in both hydrophobic channels of the
toxin [65]. The C-terminal region of the protein (residues 115–129) is colored in blue and residues Lys20, Lys115and Arg118 are highlighted in stick
representation. The crystallographic models of BthTX-I (PDB ID 3HZD) and BthTX-I/PEG4000 (PDB ID 3IQ3) are employed for step 1 and 2
representations of the apo and complexed forms of homodimeric Lys49-PLA2s, respectively. RA impairs the transition between steps 1 and 2: the
inhibitor interacts with the Lys49-PLA2 at the entrance of the hydrophobic channels, consequently affecting the ability of lipid tails of membrane
phospholipids to be inserted in the toxin hydrophobic channels.
doi:10.1371/journal.pone.0028521.g008
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inhibitor interacts with atoms of both protomers (Figure 5),
however conformational changes are observed only in the C-
terminus of protomer B (Figure 7).
In conclusion, we have demonstrated that RA interacts with
PrTX-I at the entrance of its hydrophobic channel and that the
presence of ligand bound outside the well-characterized ‘‘myotoxic
site’’ at the C-terminus of Lys49-PLA2 affect the toxin’s ability to
destabilize muscle membranes. Considering the two-step mecha-
nism by which Lys49-PLA2s may act [65] it is possible to propose
different means to inhibit these myotoxins: i) by inhibition of the
‘‘myotoxic site’’ (e.g. with heparin [99]), ii) by physical inhibition of
the hydrophobic channel (e.g. with PEG400 [39]) or by preventing
its occupation (e.g. with RA). The combination of these strategies
may lead to more successful methods to inhibit bothropic Lys49-
PLA2s myotoxins within the context of snakebite treatment by the
development of inhibitory compounds that may serve as an
adjuvant to serum therapy.
Atomic coordinates
The PrTX-I/RA coordinates have been deposited in the
Protein Data Bank with identification code 3QNL.
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